Leadership in health care private equity since 1986

The Latest News

January 25, 2018

Exagen Diagnostics announces collaboration with GSK to drive greater awareness about challenges facing lupus diagnosis and management>

Shared goal to help SLE patients shorten the time to their diagnosis, which is nearly six years on average, and to facilitate improved patient health outcomes

January 23, 2018

Surefire Medical Appoints Mary T. Szela CEO and President>

Szela brings nearly 30 years of progressive leadership experience to Surefire building global billion-dollar brands, advancing pipeline products in the biotechnology, medical products, and pharmaceutical industries while creating value for stakeholders.

March 27, 2017

SafeOp Surgical Files for Ninth Patent>

Latest EPAD™ System innovation reduces false positive alerts during surgical nerve monitoring

February 16, 2017

National Rheumatology Group AARA Embraces Exagen Diagnostics' Novel Method to Collect and Test for Widely Used Therapies in Lupus and Rheumatoid Arthritis>

Novel AVISE Touch capillary blood collection method eliminates the need for venipuncture blood draw

February 15, 2017

VERASENSE™ Named Edison Awards Finalist>

OrthoSensor to be recognized at Edison Awards Gala on April 20 in New York

March 08, 2016

OrthoSensor And IM-Tech Enter Into A Strategic Partnership>

OrthoSensor, Inc., the leader in sensor-assisted total knee arthroplasty, and IM-Tech, a subsidiary of Woori ETI Co., Ltd. a leading company in electronic components for telecommunications and consumer electronics industries, entered into a strategic partnership agreement that includes research and development collaboration, manufacturing, and capital investment.

October 29, 2015

Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System at CIRSE>

Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System at CIRSE

July 27, 2015

Two Members of the Tullis Health Investors Advisory Board, Dr. David Leffell and Dr. Barbara Bierer, Become Venture Partners>

Tullis Health Investors is pleased to announce that Dr. David Leffell, Chair of the Tullis Health Investors Advisory Board, and Dr. Barbara Bierer, a long-time member of the Board, have each taken additional responsibilities as Venture Partners of Tullis. 

July 15, 2015

Tullis Growth Fund, L.P. Invests in Surefire Medical>

In June 2015, Tullis Growth Fund, L.P. (TGF) closed an investment into Surefire Medical. The company develops, manufactures, and markets medical devices, in particular catheters to precisely deliver therapeutic drugs in liver cancer patients. 

May 07, 2015

Alexion to Acquire Synageva>

Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases.

May 07, 2015

Professor Das Narayandas Joins the Advisory Board of Tullis Health Investors>

We are pleased to announce that Professor Das Narayandas, BTech, PGDM, PhD, has joined the Advisory Board of Tullis Health Investors. Das Narayandas is the James J. Hill Professor of Business Administration at the Harvard Business School. He is currently the Senior Associate Dean, Chair, Harvard Business Publishing, and Senior Associate Dean, Chair, Executive Education. 

March 13, 2015

Orthosensor Completes $19 Million Funding Round; Second investment for Tullis Growth Fund>

The Tullis Growth Fund has completed its second investment into Orthosensor, a Florida-based maker of knee and joint implant placement technologies.

November 25, 2014

Tullis Advisory Board Member Dr. David Leffell in the News>

Dr David Leffell quoted in Wall Street Journal article: New Drugs Treat Advanced Stages of a Common Skin 

 

October 20, 2014

Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award>

Valeritas, Inc., a leader in simple, disposable basal-bolus insulin delivery technology designed for patients with Type 2 diabetes, announced today that it has received a 2014 Cardinal Health Supply Chain Excellence Award. The award was presented October 16th at Cardinal's annual Business Partners Conference in Columbus, Ohio.

September 22, 2014

Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer>

Synageva BioPharma Corp. ("Synageva") (GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating Officer.  Reporting directly to Sanj K. Patel, President and Chief Executive Officer, Robert will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations.

September 22, 2014

Exagen Diagnostics Files for IPO>

Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it has the potential to raise up to $69 million. The company plans to list on the Nasdaq Global Market under the symbol of EXDX. The underwriters for this initial offering are Leerink Partners, William Blair and Baird.

July 01, 2014

ElectroCore’s funding is $10 million oversubscribed by all parties including Merck’s GHI fund to bring it to $50 million>

electroCore, the New Jersey based electroceutical company has announced that its successful funding initiative of $40 million, announced in April last year, has been oversubscribed by $10 million by all parties including Merck’s Global healthcare Innovation fund and private equity groups Easton Capital and Core Ventures. The final tranche of $15 million of the $40 million was optional but following discussions between the investors this was not only made compulsory but increased by $10 million to a total of $50 million. 

June 03, 2014

Synageva BioPharma™ Highlights Data Presentations And Satellite Symposium At The European Atherosclerosis Society Congress>

Synageva BioPharma Corp. (Synageva) (GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced data presentations and a company-sponsored satellite symposium at the European Atherosclerosis Society (EAS) Congress being held May 31-June 3, 2014 in Madrid, Spain. 

May 15, 2014

Interim Analysis Suggests that Delivery of Insulin via Valeritas' V-Go® Shows Promise in Improving Glycemic Control for Patients with Type 2 Diabetes Previously Taking Long-Acting Insulin>

Valeritas, makers of the V-Go® Disposable Insulin Delivery Device, announced interim analysis data from SIMPLE, a prospective observational study, today that suggest patients with Type 2 diabetes who switched to V-Go therapy from their previous baseline treatment of long-acting insulin with or without oral medications experienced significantly improved glycemic control and a reduction in total daily insulin dose. The interim results, part of a planned interim analysis performed as part of the twelve month study, were presented at the American Association of Clinical Endocrinologists (AACE) 23rd annual scientific and clinical congress.